<DOC>
	<DOCNO>NCT00246220</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety three dose prolonged-release methylphenidate ( central nervous system ( CNS ) stimulant ) adult patient attention deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>A Study Effectiveness Safety Prolonged-release Methylphenidate Hydrochloride Adult Patients With Attention Deficit/Hyperactivity Disorder .</brief_title>
	<detailed_description>Stimulant therapy mainstay pharmacologic treatment attention deficit/hyperactivity disorder ( ADHD ) child adolescent . Methylphenidate commonly prescribe frequently study stimulant medication child adolescent disorder . It widely acknowledge scientific literature ADHD often persist adulthood . Few large-scale , rigorous study conduct investigate effectiveness safety stimulant therapy treat ADHD adult . This multicentre , double-blind , randomise , placebo-controlled , parallel group , dose-response study compare three dos prolonged-release methylphenidate ( 18 , 36 , 72 mg once-daily ) versus placebo adult patient ADHD . The primary efficacy outcome change baseline end double-blind phase sum inattention hyperactivity/impulsivity subscale score investigator-rated Conners ' Adult ADHD Rating Scale ( CAARS ) . Additional measure effectiveness include follow scale : CAARS-self report , rate item pertain patient 's behavior/problems ; Clinical Global Impression ( CGI ) , rate severity patient 's illness ; Sheehan 's Disability Scale ( SDS ) , measure extent patient 's work , social life leisure activity home life family responsibility impair his/her symptom ; Quality Life Enjoyment Satisfaction Questionnaire ( Q-LES-Q ) ; Global Assessment Effectiveness . Safety tolerability monitor throughout study . The study hypothesis prolonged-release methylphenidate take once-daily produce clinically significant improvement compare placebo measure inattention hyperactivity/impulsivity Conners ' Adult ADHD Rating Scale patient adult ADHD . Prolonged-release methylphenidate 18 , 36 72 mg oral capsule , placebo , take once-daily 5 week . Eligible patient may continue prolonged-release methylphenidate open-label extension study additional 7 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Adults diagnosis Attention Deficit/Hyperactivity Disorder ( ADHD ) accord DSMIV criterion ADHD symptom childhood adulthood , symptoms present age 7 year continue meet DSMIV criterion time assessment . ( ADHD diagnose symptom well account another psychiatric disorder . ) Patients know nonresponder methylphenidate know child nonresponder methylphenidate treat methylphenidatecontaining medication within 1 month start study clinically unstable psychiatric condition include , limited following : acute mood disorder , bipolar disorder , acute obsessivecompulsive disorder , antisocial personality disorder , borderline personality disorder family history schizophrenia affective psychosis patient motor tic history Tourette 's syndrome , substance abuse dependence disorder , eat disorder , mental retardation use medication may affect evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Attention deficit/hyperactivity disorder</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>central nervous system stimulant</keyword>
</DOC>